Search

Blog

We constantly analyse the legislation and regulatory information related to a specific medicine in order to appraise the context in which the company operates

We put all our knowledge into play to anticipate risks and seize every opportunity, but above all to understand the rules of the game and display our creativity with them. We spread material and information proceeding from our investigation into medicines governance and regulatory science. In fact, we deem it necessary to be aware of the complexity of the results of research, regulation and drug policy in order to be able to work in a cultural ecosystem aiming both at promoting research outcomes that are useful to patients and at encouraging politicians to protect people’s health. The wider the knowledge of each interest group, the greater their ability to interact and achieve transparency of procedures and health protection.

  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
All
  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
AIFA meets' event

AIFA meets

On 12 September, the 'AIFA Incontra' initiative was held at the agency's institutional headquarters in Via del Tritone, a new way of communicating with the ...
Read more "

Pharma Value at the 2nd GIRF Congress - ISPOR Group Rome for Future

On 3 and 4 July, the 2nd GIRF Congress - ISPOR Roma for Future Group - was held in Milan, ...
Read more "

From Horizon scanning to the new HTA Regulation

New regulations in the legislative landscape impose a high focus on access to medicines in the near future. As of 1 January 2025, it will become operational ...
Read more "

Special on Commission No. 3

For our colleagues outside Italy who watch us with attention and amazement, we are here to translate for you what is happening ...
Read more "

Pharma Value analysis of the National Rare Disease Plan 2023-2026 - focus drugs

On Monday, 24 May 2023, at the State-Regions Conference, the approval of the National Plan for Rare Diseases 2023-2026 was ratified, after seven years of ...
Read more "
special 3 on DM AIFA

Special Commission Update No. 3 - Towards the reform of the governance of the Italian Medicines Agency and the Single Commission: where are we?

Update 20 November 2023 The extraordinary State-Regions Conference held on 16 November 2023, sanctioned the long-awaited agreement on the draft regulation of the ...
Read more "
article cover customer feedback

What they say about us, first results of our customer feedback request

As of January 2023, Pharma Value started, in cooperation with the soc. coop. Prospects, a work of evaluation and analysis ...
Read more "
EPA Congress on Orphan Drugs

Next steps for the revision of the Orphan Drug Regulation

The European Commission's official proposal is due to be published on 29 March 2023, but during the World Evidence, Pricing and ...
Read more "
Valeria Viola at OSSFOR report presentation

Proposed regulatory reform of 648/96 for fast access to orphan drugs

Rome, 31 January 2023. The following text summarises the speech by Valeria Viola, owner of Pharma Value, during the presentation of the VI ...
Read more "
en_GB